FDA Biological Response Modifiers Advisory Committee
Executive SummaryAgency's newest advisory committee will hold its first meeting July 30-31. The panel was formed to help with FDA reviews of cytokines and other biologicals seeking approval for use in treating cancer. The meeting's agenda has not been released, but reportedly, the committee's first reviews could involve GM-CSF and G-CSF. PLAs for GM-CSF products were filed earlier this year by Immunex and Schering-Plough. Amgen submitted a PLA for G-CSF in December.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.